The imminent departure of US Food & Drug Administration Principal Deputy Commissioner Amy Abernethy is clearly a loss of leadership for an agency already living through an uncertain transition period, but does leave open the ability for the next commissioner (whether it is Acting Commissioner Janet Woodcook or another nominee) to choose a number two that reflects that individual’s priorities.
Woodcock announced Abernethy’s intention to leave FDA in a 23 March email to staff. In an interview...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?